Oral and Maxillofacial Pathology: Interleukin‐1 β, interleukin‐6, and tissue inhibitor of metalloproteinase‐1 in the synovial fluid of the temporomandibular joint with respect to cartilage destruction

Abstract

OBJECTIVE: The distribution and biological roles of interleukin (IL)-1␤, IL-6, and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the synovial fluid of patients with non-inflammatory chronic temporomandibular joint (TMJ) disorders were evaluated in relation to pain upon joint movements and X-ray and magnetic resonance imaging (MRI) findings. MATERIALS AND METHODS: TMJ aspirates were obtained from 48 patients (48 joints) with chronic TMJ disorders and from 18 controls (18 joints). The IL-1␤ and IL-6 levels in the aspirates were determined by using an enzyme-linked immunosorbent assay and the TIMP-1 level was measured by an enzyme immunoassay. Following examinations for pain upon joint movements and Xray and MRI observations, the IL-1␤, IL-6, and TIMP-1 levels and frequencies of their detection were compared. RESULTS: The IL-1␤ level and frequency of detection showed no correlation with pain upon joint movements or with the X-ray and MRI findings. In the frequency of detection of IL-6, there were significant differences between control (no detection) and all chronic TMJ disorder groups that were classified by imaging diagnosis (P Ͻ 0.001). A correlation was also noted between the presence of IL-6 and pain upon joint movements. The IL-6 level was correlated with the TIMP-1 level and with pain upon joint movements. TIMP-1 level was correlated with pain upon joint movements. The TIMP-1 was present in higher level from patients with chronic TMJ disorders who exhibited osseous changes on the X-ray images. CONCLUSION: The results indicated that the IL-6 and TIMP-1 levels in the TMJ aspirates of patients with chronic TMJ disorders have been raised. The former was not detected in the TMJ aspirates of the control. These findings suggest that IL-6 and TIMP-1 might play a role Correspondence: Chisei Shinoda, in the etiology of chronic TMJ disorders, but further studies are needed to validate this. Oral Diseases (2000) 6, 383-390 Keywords: interleukin; tissue inhibitor of metalloproteinase-1; biochemical analysis; synovial fluid; temporomandibular joint IL-1␤, IL-6 and TIMP-1 in the synovial fluid of the TMJ C Shinoda and S Takaku

Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation

“…The significant increase in IL-6 and FcγRIII, but not IL-1β (Figure 2,3a), by the higher dose of blank MPs is consistent with TLR activation. IL-1β and IL-6 were selected for quantification because they are elevated in the TMJs of patients and animal models with painful inflammation [19–21]. TLR stimulation by microparticles has been shown to trigger IL-6-mediated inflammation [17].…”

IL-1β Suppresses the Formation of Osteoclasts by Increasing OPG Production via an Autocrine Mechanism Involving Celecoxib-Related Prostaglandins in Chondrocytes

“…Cytokines released at sites of inflammation and infection can alter the normal processes of cartilage turnover, resulting in its pathological destruction or formation [29], and the levels of inflammatory cytokines are higher than normal in the synovial fluid of patients with TMJ arthrosis [30, 31]. IL-1 β in synovial fluid not only plays a central role in the pathophysiology of cartilage damage and degradation, but is also associated with pain and hyperalgesia in TMJ.…”

Quantification of condylar resorption in temporomandibular joint osteoarthritis

“…TMJ osteoarthritis(OA) is a local inflammatory condition which occurs when the dynamic equilibrium between the breakdown and the repair of joint tissue is compromised. The spectrum of clinical and pathological presentation of TMJ OA range from structural and functional failure of the joint with disc displacement and degeneration, to subchondral bone alterations (erosions), bone overgrowth (osteophytes), loss of articular fibrocartilage, and synovitis._Local inflammatory processes in the TMJ are known to share common pathways with pain and bone resorption 4-9. However, the factors which mitigate the morphological changes and clinical signs and symptoms (such as pain and joint sounds) is unknown 10.…”